Features include always present findings: Microscopic hematuria, Glomerular C3 deposition, and Glomerular subendothelial electron-dense deposits; and very common findings: Mesangial matrix expansion, Mesangial hypercellularity, and Thickening of glomerular capillary wall. 9 total HPO annotations.

CFHR5 encodes complement factor H related 5 (569 aa). Involved in complement regulation. The dimerized forms have avidity for tissue-bound complement fragments and efficiently compete with the physiological complement inhibitor CFH Highest expression in Liver (39.2 TPM) and Testis (0.1 TPM).

C3 glomerulonephritis is associated with mutations in the CFHR5 gene on chromosome 1.

CFHR5 is classified as a druggable target (Druggable Genome category) with score 0.0.

Genetic testing for CFHR5 is available. Testing is considered confirmatory for diagnosis.

Biomarker and diagnostic research for C3 glomerulonephritis has been reported in the published literature.

Phenotype severity distribution: 3 always present features, 3 very common features, 1 common feature.

3 clinical trials registered, 1 recruiting. Interventions under study include drug therapy. Pipeline includes 1 PHASE3, 2 PHASE2. Research is sponsored by a mix of industry and academic institutions.

81 publications have been identified in PubMed for C3 glomerulonephritis. Research spans Case Report / Case Series (33%), Review / Meta-Analysis (21%), and Basic Science / Preclinical (15%).